Ulcerative Colitis Market Size was ~USD 8,400 million in 2023 and is anticipated to grow with a significant CAGR by 2034, estimates DelveInsight | Janssen Pharmaceuticals, Takeda Pharmaceuticals, Arena Pharmaceuticals/Pfizer, Abivax, Reistone Biopharma

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Ulcerative Colitis Market with DelveInsight's In-Depth Report @ Ulcerative Colitis Market Size- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Ulcerative Colitis Market Report:
• In January 2025, Rise Therapeutics announced that the FDA has accepted its IND application to initiate a Phase 1 cancer trial for R-5780, making it the company's fourth clinical program. Ongoing studies for other products are targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
• In December 2024, Celltrion announced that the FDA has approved STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for subcutaneous injection or intravenous infusion. This approval includes adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• In December 2024, Accropeutics Inc. announced that the FDA has cleared its Phase II trial for AC-101, a RIPK2 inhibitor, to treat moderate-to-severe ulcerative colitis. The 12-week, multi-regional, randomized trial will evaluate the safety and efficacy of the treatment.
• In 2023, the ulcerative colitis market size in the US was the largest among the 7MM, reaching approximately USD 5,900 million, with expectations for further growth by 2034.
• Emerging therapies such as obefazimod (Abivax), risankizumab (AbbVie/Boehringer Ingelheim), guselkumab (Janssen), and others are set to broaden the treatment options for ulcerative colitis.
• The total number of diagnosed prevalent cases of Ulcerative Colitis in the 7MM was approximately 3,114,000 in 2023 and is expected to rise throughout the forecast period.
• In 2023, the United States had the largest diagnosed prevalent ulcerative colitis population, representing approximately 47% of the total 7MM. Meanwhile, Germany and Japan each accounted for around 10% of the overall 7MM population share.
• Estimates indicate that in 2023, the diagnosed prevalent cases of Ulcerative Colitis in the EU4 and the UK were approximately 521,000 mild cases and 860,000 moderate to severe cases. These numbers are expected to rise during the forecast period.
• Key Ulcerative Colitis Companies: Janssen Pharmaceuticals, Takeda Pharmaceuticals, Arena Pharmaceuticals/Pfizer, Abivax, Reistone Biopharma, Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• The Ulcerative Colitis epidemiology based on severity-based cases analyzed that moderate-to-severe UC cases accounts for ~55% of the total cases and the rest of the cases falls under mild category.
• The Ulcerative Colitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

Stay ahead in the Ulcerative Colitis Therapeutics Market with DelveInsight's Strategic Report @ Ulcerative Colitis Market Outlook- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ulcerative Colitis Epidemiology Segmentation in the 7MM
• Total Prevalence of Ulcerative Colitis
• Prevalent Cases of Ulcerative Colitis by severity
• Gender-specific Prevalence of Ulcerative Colitis
• Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Ulcerative Colitis Therapies and Companies
• SIMPONI (golimumab): Janssen Pharmaceuticals
• ENTYVIO (vedolizumab): Takeda Pharmaceuticals
• Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
• ABX464 (obefazimod): Abivax
• SHR0302 (Ivarmacitinib): Reistone Biopharma
• VE202: Vedanta Biosciences, Inc.
• PL8177 Placebo: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Vixarelimab: Genentech, Inc.
• Etrasimod: Pfizer
• Efavaleukin alfa: Amgen
• ABBV-668: AbbVie
• NX-13: Landos Biopharma Inc.
• 5-ASA: Ferring Pharmaceuticals
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• VTX002: Oppilan Pharma Ltd
• AJM300: EA Pharma Co., Ltd.

Get In-Depth Knowledge on Ulcerative Colitis Market Trends and Forecasts with DelveInsight @ Ulcerative Colitis Treatment Market- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ulcerative Colitis Market Strengths
• With the market dynamics shifting towards medications with oral ROA, emergence of therapies like, BT-11, AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
• Robust emerging pipeline with novel MOAs with less immunogenicity such as cobitolimod, BBT-401, Omilancor, and others are likely to strengthen the market.

Ulcerative Colitis Market Opportunities
• There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile ofupcoming drugs.
• Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

Unlock Strategic Insights with DelveInsight's Comprehensive Ulcerative Colitis Market Report @ Ulcerative Colitis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ulcerative Colitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Ulcerative Colitis Companies: Janssen Pharmaceuticals, Takeda Pharmaceuticals, Arena Pharmaceuticals/Pfizer, Abivax, Reistone Biopharma, Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative Colitis Market Access and Reimbursement

To know more about Ulcerative Colitis companies working in the treatment market, visit @ Ulcerative Colitis Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Ulcerative Colitis Market Report Introduction
2. Executive Summary for Ulcerative Colitis
3. SWOT analysis of Ulcerative Colitis
4. Ulcerative Colitis Patient Share (%) Overview at a Glance
5. Ulcerative Colitis Market Overview at a Glance
6. Ulcerative Colitis Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative Colitis
9. Ulcerative Colitis Current Treatment and Medical Practices
10. Ulcerative Colitis Unmet Needs
11. Ulcerative Colitis Emerging Therapies
12. Ulcerative Colitis Market Outlook
13. Country-Wise Ulcerative Colitis Market Analysis (2020-2034)
14. Ulcerative Colitis Market Access and Reimbursement of Therapies
15. Ulcerative Colitis Market Drivers
16. Ulcerative Colitis Market Barriers
17. Ulcerative Colitis Appendix
18. Ulcerative Colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of the Top Selling Market Research Reports in 2025
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
vulvar cancer market- https://www.delveinsight.com/report-store/vulvar-cancer-pipeline-insight
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
cart pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.